PA
CBIO

Perceptive Advisors’s Crescent Biopharma CBIO Stock Holding History

Perceptive Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.8M Sell
206,942
-246,744
-54% -$2.83M 0.07% 80
2025
Q4 		$5.38M Hold
453,686
– – 0.1% 91
2025
Q3 		$5.39M Hold
453,686
– – 0.16% 71
2025
Q2 		$7.32M Buy
+453,686
New +$9.6M 0.27% 57

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors's CBIO Position: Q1 2026 in Review

Perceptive Advisors reduced its Crescent Biopharma (CBIO) stake by 54% in Q1 2026, selling an estimated $2.83M and leaving 206,942 shares worth $3.8M. The position accounts for 0.07% of the portfolio, ranked #80.

Perceptive Advisors first reported a position in CBIO in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.32M in Q2 2025. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Perceptive Advisors held 206,942 shares of Crescent Biopharma worth $3.8M as of Q1 2026.
  • Perceptive Advisors sold 246,744 Crescent Biopharma shares in Q1 2026, an estimated $2.83M.
  • Crescent Biopharma made up 0.07% of Perceptive Advisors's portfolio in Q1 2026, its #80 holding.
  • Perceptive Advisors first reported a position in Crescent Biopharma in Q2 2025 and has held it in 4 quarters since.
  • Perceptive Advisors's Crescent Biopharma position peaked at $7.32M in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.